content: <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <headerData>
  <submissionType>144</submissionType>
  <filerInfo>
  <filer>
  <filerCredentials>
  <cik>0001833157</cik>
  <ccc>XXXXXXXX</ccc>
  </filerCredentials>
  </filer>
  <liveTestFlag>LIVE</liveTestFlag>
  </filerInfo>
  </headerData>
  <formData>
  <issuerInfo>
  <issuerCik>0001823239</issuerCik>
  <issuerName>MARAVAI LIFESCIENCES HOLDINGS, INC.</issuerName>
  <secFileNumber>001-39725</secFileNumber>
  <issuerAddress>
  <street1 xmlns="http://www.sec.gov/edgar/common">10770 Wateridge Circle</street1>
  <street2 xmlns="http://www.sec.gov/edgar/common">Suite 200</street2>
  <city xmlns="http://www.sec.gov/edgar/common">San Diego</city>
  <stateOrCountry xmlns="http://www.sec.gov/edgar/common">CA</stateOrCountry>
  <zipCode xmlns="http://www.sec.gov/edgar/common">92121</zipCode>
  </issuerAddress>
  <issuerContactPhone>858-546-0004</issuerContactPhone>
  <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Maravai Life Sciences Holdings, LLC</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
  <relationshipsToIssuer>
  <relationshipToIssuer>Owner</relationshipToIssuer>
  </relationshipsToIssuer>
  </issuerInfo>
  <securitiesInformation>
  <securitiesClassTitle>Class A common stock, par value $0.01 per share</securitiesClassTitle>
  <brokerOrMarketmakerDetails>
  <name>Goldman Sachs &amp; Co. LLC</name>
  <address>
  <street1 xmlns="http://www.sec.gov/edgar/common">200 West Street</street1>
  <city xmlns="http://www.sec.gov/edgar/common">New York</city>
  <stateOrCountry xmlns="http://www.sec.gov/edgar/common">NY</stateOrCountry>
  <zipCode xmlns="http://www.sec.gov/edgar/common">10282</zipCode>
  </address>
  </brokerOrMarketmakerDetails>
  <noOfUnitsSold>8409946</noOfUnitsSold>
  <aggregateMarketValue>90659217.88</aggregateMarketValue>
  <noOfUnitsOutstanding>132830872</noOfUnitsOutstanding>
  <approxSaleDate>05/28/2024</approxSaleDate>
  <securitiesExchangeName>Nasdaq</securitiesExchangeName>
  </securitiesInformation>
  <securitiesToBeSold>
  <securitiesClassTitle>Class A common stock, par value $0.01 per share</securitiesClassTitle>
  <acquiredDate>11/19/2020</acquiredDate>
  <natureOfAcquisitionTransaction>Pre-IPO reorganization</natureOfAcquisitionTransaction>
  <nameOfPersonfromWhomAcquired>Maravai LifeSciences Holdings, Inc.</nameOfPersonfromWhomAcquired>
  <isGiftTransaction>N</isGiftTransaction>
  <amountOfSecuritiesAcquired>168654981</amountOfSecuritiesAcquired>
  <paymentDate>11/19/2020</paymentDate>
  <natureOfPayment>Securities of the issuer were received in connection with a series of reorganization transactions prior to the issuer's IPO.</natureOfPayment>
  </securitiesToBeSold>
  <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
  <remarks>(1) Based on the closing price on May 28, 2024 of $10.78. (2) As of May 2, 2024 (as reported on the Issuer's Form 10-Q for the quarter ended March 31, 2024, filed with the Securities and Exchange Commission on May 9, 2024).</remarks>
  <noticeSignature>
  <noticeDate>05/28/2024</noticeDate>
  <signature>/s/ Kevin Herde</signature>
  </noticeSignature>
  </formData>
  </edgarSubmission>
metadata_documents: [{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 3225}]
text: 144
  0001833157
  XXXXXXXX
  LIVE
  0001823239
  MARAVAI LIFESCIENCES HOLDINGS, INC.
  001-39725
  10770 Wateridge Circle
  Suite 200
  San Diego
  CA
  92121
  858-546-0004
  Maravai Life Sciences Holdings, LLC
  Owner
  Class A common stock, par value $0.01 per share
  Goldman Sachs & Co. LLC
  200 West Street
  New York
  NY
  10282
  8409946
  90659217.88
  132830872
  05/28/2024
  Nasdaq
  Class A common stock, par value $0.01 per share
  11/19/2020
  Pre-IPO reorganization
  Maravai LifeSciences Holdings, Inc.
  N
  168654981
  11/19/2020
  Securities of the issuer were received in connection with a series of reorganization transactions prior to the issuer's IPO.
  Y
  (1) Based on the closing price on May 28, 2024 of $10.78. (2) As of May 2, 2024 (as reported on the Issuer's Form 10-Q for the quarter ended March 31, 2024, filed with the Securities and Exchange Commission on May 9, 2024).
  05/28/2024
  /s/ Kevin Herde